ClinicalTrials.gg
CompletedNCT05215847Updated Feb 11, 2025Results posted

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

A Phase 2 interventional study of ARD-101 in Bariatric Surgery, Obesity and Weight Gain, sponsored by Aardvark Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Aardvark Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).

Read the detailed description

This is a Phase 2, open-label study to investigate the safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass). This study has a planned enrollment of 30 subjects (approximately 15 for each preceding surgical procedure) and will be conducted in a single center in the United States.

The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (EOS Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101.

02

Conditions studied

  • Bariatric Surgery
  • Obesity
  • Weight Gain

Keywords

  • Obesity
  • Bariatric Surgery
  • Weight Gain
  • Anti-Obesity Agents
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 12 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Aardvark Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 18-75 years of age
  • Willing and able to provide signed and dated prior to any study-related procedures and willing and able to comply with all study procedures
  • (BMI) of 35-60 kg/m2 during the Screening Period
  • Status of at least 1-year post sleeve gastrectomy or gastric bypass surgery. Subjects must have a documented weight loss of at least 50% of their excess weight at their nadir, and must have regained at least 20% of their nadir weight loss. Excess weight is defined as maximum preoperative weight - weight corresponding to a BMI of 25 kg/m2
  • Subjects with rescue surgery (e.g. gastric band to sleeve gastrectomy or gastric bypass; sleeve gastrectomy to gastric bypass) will be allowed, with time since second surgery of at least 12 months.
  • Subjects with a history of revision procedures will be allowed if at least 6 months have passed since the procedure and weight has not deviated more than 5% in the 3 months prior to enrollment
  • No abnormal findings or abnormalities of clinical significance in vital signs, physical examination, clinical laboratory tests (CBC, urinalysis, blood biochemistry, coagulation, pregnancy test (females), urine drug test, nicotine test, etc.), 12-lead (ECG) during the Screening Period
  • Serum creatinine, alkaline phosphatase, hepatic enzymes (, alanine aminotransferase) and total (unless the subject has documented Gilbert syndrome) not exceeding 1.5-fold the upper laboratory norm and estimated (eGFR) >30 mL/min
  • Standard 12-lead ECG parameters after 10minutes resting in supine position in the following ranges; 120 ms \<PR \<220 ms, QRS \<120 ms, \<= 430 ms if male, \<= 450 ms if female and normal ECG tracing unless the Investigator considers an ECG abnormality within described limits to be not
  • Stable or well controlled blood pressure per Investigator's judgement during the Screening Period. Specifically: Vital signs after 10 minutes sitting in a chair (feet on floor, back supported):

    i. 95 mmHg \< systolic blood pressure (SBP) \<160 mmHg, ii. 45 mm Hg \< diastolic blood pressure (DBP) \<100 mm Hg, iii. 40 bpm \< heart rate (HR) \<100 bpm.

  • Prediabetes- defined as a fasting blood glucose between 100-125 mg/dL OR an between 5.7-6.5% at screening
  • Type 2 diabetes- Defined as previous diagnosis by a healthcare professional OR a fasting blood glucose > 126 mg/dL OR HbA1c > 6.5% at screening.
  • Patients with type 2 diabetes treated with metformin may be enrolled. However, patients with type 2 diabetes on any other therapy will be excluded.
  • Female subjects must have negative serum pregnancy test and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single barrier method (i.e., sponge), or a double-barrier method of (i.e., condom with spermicide) or abstinence must be used/practiced throughout the study and for 90 days following last dose of study medication; for effective form of birth control.
  • Females of non-, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, bilateral tubal ligation, bilateral salpingectomy, or bilateral tubal occlusion) or for at least 12 months (may be confirmed with a screening follicle stimulating hormone (FSH) level in the post-menopausal lab range), do not require contraception during the study.
  • Males with female partners of childbearing potential must agree to a double-barrier method if participants become sexually active during the study and for 90 days following the last dose of the study medication. Male subjects must not donate sperm for 90 days following their participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Any relevant gastrointestinal (GI) surgery (excluding the gastric bypass or sleeve gastrectomy) per Investigator judgement
  • History of significant drug or anaphylaxis
  • Participation in a weight loss program or clinical trial for weight loss within the 3 months prior to enrollment
  • Received any experimental drugs or devices or have participated in a clinical study within 30 days prior to enrollment
  • Diabetes treatment (unless metformin as outlined), or chronic oral , or treatment with immune modulators, anti-obesity drugs, chronic opiate therapy, or antipsychotic medications
  • Currently receiving any drug-based therapy for weight management
  • Thyroid-stimulating hormone (TSH) level is outside of normal limit during the Screening Period
  • The presence of diseases with abnormal clinical manifestations that need to be excluded based on their possible contribution to weight loss or weight gain, including but not limited to nervous, cardiovascular, blood and lymphatic system, immune, renal, hepatic, gastrointestinal, respiratory, metabolic and skeletal diseases during the Screening Period
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, Functional Class II-IV heart failure, or within 6 months prior to Visit 1
  • Any not considered cured (except focal, treated basal cell carcinoma and squamous cell carcinoma of the skin); a participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years
  • History of major depressive disorder or history of other severe psychiatric disorders (e.g., schizophrenia or bipolar disorder) within the last 2 years.
  • Donated ≥200 mL of blood (blood components) or had massive blood loss, received blood transfusion or blood products within 3 months prior to enrollment
  • Planned sperm/egg donation within 6 months post enrollment
  • Positive urine drug test (morphine, methamphetamine, ketamine, ecstasy, and cannabis) during the Screening Period
  • History of consuming more than 14 units of alcoholic beverages per week or of alcoholism or drug/chemical/substance abuse within past 2 years prior to enrollment (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits)
  • Smoking any amount within 3 months prior to enrollment
  • Excessive consumption of tea, coffee, and/or caffeinated beverages (more than 8 cups, 250 mL for each cup) every day within 3 months prior to enrollment
  • Symptomatic viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to enrollment
  • History of antibody, antibody or virus surface antigen
  • A history of psychiatric and psychological condition that, in the judgment of the investigator, may interfere with the planned treatment and follow-up, affect subject compliance or place the subject at high risk from treatment-related complications
  • Poor venous access or inability to tolerate venipuncture
  • Any condition or active drug treatment that the investigator or primary physician believes may not be appropriate for participating in the study
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    ARD-101

    Dose 200 mg of ARD-101, twice daily for 28 days

    Drug: ARD-101

Interventions

  • Twice daily, oral administration

06

What researchers measure

Primary outcomes

  1. Relative Change in Body Weight (%)

    The percent total weight change at the end of treatment from baseline

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAE)

    The incidence of treatment-emergent adverse events (TEAE) during the treatment period

    Time frame: Days 1-28

  2. Change in Blood Lipid Concentrations

    The change in blood lipid concentrations (total cholesterol, triglyceride, high density lipoprotein cholesterol, and low-density lipoprotein cholesterol) at the end of treatment from the baseline

    Time frame: Run-in Visit (baseline), Day 28

  3. Change in Waist Circumference

    The change in waist circumference from baseline to end of treatment

    Time frame: Baseline and Day 28

  4. Change in Hemoglobin A1c

    The change in glycated hemoglobin (HbA1c) at the end of treatment from the baseline

    Time frame: Screening (baseline), Day 28

Other outcomes

  1. Categorical Weight Loss

    Proportion of subjects who lose \< 5% and ≥ 5% initial weight

    Time frame: Run-in Visit (baseline), Day 28

  2. Circulating Levels of Glucagon-like Peptide (GLP)-1 (Pmol) During Mixed-Meal Tolerance Test (MMTT) at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of glucagon-like peptide (GLP)-1 (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for mixed-meal tolerance test (MMTT) at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  3. Circulating Levels of Cholecystokinin (CCK) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of cholecystokinin (CCK) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  4. Circulating Levels of Peptide YY (PYY) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of peptide YY (PYY) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  5. Circulating Levels of Amylin (Pmol) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of amylin (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  6. Circulating Levels of Glucose-dependent Insulinotropic Polypeptide (GIP) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of glucose-dependent insulinotropic polypeptide (GIP) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  7. Circulating Levels of Ghrelin (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of ghrelin (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  8. Circulating Levels of Leptin (ng/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of leptin (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  9. Circulating Levels of Adiponectin (mcg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of adiponectin (mcg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  10. Circulating Levels of Glucagon (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

    Circulating levels of glucagon (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

    Time frame: Run-in Visit (baseline), Day 1, Day 28

  11. Serum Levels of Glucose (mg/dL) During MMTT at Baseline and on Day 28

    Serum levels of glucose (mg/dL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

    Time frame: Run-in Visit (baseline), Day 28

  12. Serum Levels of Insulin (uIU/mL) During MMTT at Baseline and on Day 28

    Serum levels of insulin (uIU/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

    Time frame: Run-in Visit (baseline), Day 28

  13. Serum Levels of C-peptide (ng/mL) During MMTT at Baseline and on Day 28

    Serum levels of C-peptide (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

    Time frame: Run-in Visit (baseline), Day 28

  14. Serum Levels of Free Fatty Acids During MMTT at Baseline and on Day 28

    Serum levels of free fatty acids (FFA) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

    Time frame: Run-in Visit (baseline), Day 28

  15. Circulating Levels of Interleukin (IL)-1 Beta (pg/mL) During MMTT

    Circulating levels of interleukin (IL)-1 beta (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  16. Circulating Levels of IL-6 (pg/mL) During MMTT

    Circulating levels of IL-6 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  17. Circulating Levels of IL-10 (pg/mL) During MMTT

    Circulating levels of IL-10 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  18. Circulating Levels of IL-12 p40 (pg/mL) During MMTT

    Circulating levels of IL-12 p40 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  19. Circulating Levels of IL-12 p70 (pg/mL) During MMTT

    Circulating levels of IL-12 p70 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  20. Circulating Levels of IL-17 (pg/mL) During MMTT

    Circulating levels of IL-17 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  21. Circulating Levels of Tumor Necrosis Factor (TNF)-Alpha (pg/mL) During MMTT

    Circulating levels of tumor necrosis factor (TNF)-alpha (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  22. Circulating Levels of C Reactive Protein (CRP) (mg/L) During MMTT

    Circulating levels of C reactive protein (CRP) (mg/L) at run in visit and end of treatment (day 28) performed during the MMTT

    Time frame: Run-in Visit (baseline), Day 28

  23. Body Fat Percentage

    Body fat percentage measured by bioelectrical impedance scale

    Time frame: Run-in Visit (baseline), Days 1-28

  24. Change in the Percentage of Liver Fat Content

    Change in the percentage of liver fat content assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)

    Time frame: Run-in Visit (baseline), Day 28

  25. Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    The change in homeostatic model assessment for insulin resistance (HOMA-IR) at the end of treatment from the baseline

    Time frame: Run-in Visit (baseline), Day 28

  26. Change in Fasting Blood Glucose

    The change in fasting blood glucose at the end of treatment from the baseline

    Time frame: Run-in Visit (baseline), Day 28

  27. Change in Serum Bile Acids

    Change in serum bile acids at the end of treatment compared to the baseline

    Time frame: Run-in Visit (baseline), Day 28

  28. Phenotypic Taste Test

    Phenotypic taste test (using commercially available test strips) at baseline

    Time frame: Run-in Visit (baseline)

  29. Control of Eating and Food Cravings

    Control of eating and food craving assessed by the Control of Eating Questionnaire (CoEQ), which is a 21-item questionnaire designed to assess the intensity and type of food cravings and subjective sensations of appetite and mood according to an individual's experience over the last 7 days. Items on the CoEQ are assessed by 100-mm visual analogue scales (VAS). Subjects will mark their level with a vertical line on the horizontal line of the VAS scale. The numerical value will start at 1.0 cm and end 10.0 cm. Use a ruler to determine the numerical value (to the tenth decimal) associated with the line marked by subjects. Higher score indicates less control of eating and food cravings.

    Time frame: Screening, Days 1, 15, and 28

  30. Change in Indirect Calorimetry

    Change in indirect calorimetry between Day 1 and Day 28

    Time frame: Day 1, Day 28

  31. Area Under the Curve (AUC) of Serum Level of Glucose (mg/dL) During MMTT

    Changes in AUC of serum level of glucose (mg/dL) during MMTT between baseline and Day 28

    Time frame: Run-in Visit (baseline), Day 28

  32. Area Under the Curve (AUC) of Serum Level of Insulin (uIU/mL) During MMTT

    Changes in AUC of serum level of insulin (uIU/mL) during MMTT between baseline and Day 28

    Time frame: Run-in Visit (baseline), Day 28

  33. Area Under the Curve (AUC) of Serum Level of C-peptide (ng/mL) During MMTT

    Changes in AUC of serum levels of C-peptide (ng/mL) during MMTT between baseline and Day 28

    Time frame: Run-in Visit (baseline), Day 28

  34. Changes in Fecal Microbial Species and Their Relative Abundance

    Changes in fecal microbial species and their relative abundance assessed by 16S rRNA gene sequencing

    Time frame: Day 1, Day 28

07

Results

Posted Nov 14, 2024

Participant flow

Participant flow — Overall Study
MilestoneARD-101
Started12
Completed11
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryRelative Change in Body Weight (%)

The percent total weight change at the end of treatment from baseline

Time frame:
Baseline and Day 28
Reported as:
Mean · Percent Change
Relative Change in Body Weight (%)
Percent ChangeARD-101
Relative Change in Body Weight (%)0.033 ± 1.515
SecondaryIncidence of Treatment-emergent Adverse Events (TEAE)

The incidence of treatment-emergent adverse events (TEAE) during the treatment period

Time frame:
Days 1-28
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAE)
ParticipantsARD-101
Incidence of Treatment-emergent Adverse Events (TEAE)6
Statistical analysis
  • ARD-101 ·
SecondaryChange in Blood Lipid Concentrations

The change in blood lipid concentrations (total cholesterol, triglyceride, high density lipoprotein cholesterol, and low-density lipoprotein cholesterol) at the end of treatment from the baseline

Time frame:
Run-in Visit (baseline), Day 28
Reported as:
Mean · mg/dL
Change in Blood Lipid Concentrations
mg/dLARD-101
Total Cholesterol-0.73 ± 18.23
Triglyceride2.09 ± 32.14
High density lipoprotein cholesterol-0.82 ± 9.36
Low-density lipoprotein cholesterol-0.36 ± 15.58
SecondaryChange in Waist Circumference

The change in waist circumference from baseline to end of treatment

Time frame:
Baseline and Day 28
Reported as:
Mean · Centimeters
Change in Waist Circumference
CentimetersARD-101
Change in Waist Circumference-0.7 ± 1.03
SecondaryChange in Hemoglobin A1c

The change in glycated hemoglobin (HbA1c) at the end of treatment from the baseline

Time frame:
Screening (baseline), Day 28
Reported as:
Mean · Percentage
Change in Hemoglobin A1c
PercentageARD-101
Change in Hemoglobin A1c0.04 ± 0.17
Other pre-specifiedCategorical Weight Loss

Proportion of subjects who lose \< 5% and ≥ 5% initial weight

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Glucagon-like Peptide (GLP)-1 (Pmol) During Mixed-Meal Tolerance Test (MMTT) at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of glucagon-like peptide (GLP)-1 (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for mixed-meal tolerance test (MMTT) at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Cholecystokinin (CCK) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of cholecystokinin (CCK) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Peptide YY (PYY) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of peptide YY (PYY) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Amylin (Pmol) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of amylin (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Glucose-dependent Insulinotropic Polypeptide (GIP) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of glucose-dependent insulinotropic polypeptide (GIP) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Ghrelin (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of ghrelin (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Leptin (ng/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of leptin (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Adiponectin (mcg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of adiponectin (mcg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Glucagon (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1

Circulating levels of glucagon (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.

Time frame:
Run-in Visit (baseline), Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedSerum Levels of Glucose (mg/dL) During MMTT at Baseline and on Day 28

Serum levels of glucose (mg/dL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedSerum Levels of Insulin (uIU/mL) During MMTT at Baseline and on Day 28

Serum levels of insulin (uIU/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedSerum Levels of C-peptide (ng/mL) During MMTT at Baseline and on Day 28

Serum levels of C-peptide (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedSerum Levels of Free Fatty Acids During MMTT at Baseline and on Day 28

Serum levels of free fatty acids (FFA) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Interleukin (IL)-1 Beta (pg/mL) During MMTT

Circulating levels of interleukin (IL)-1 beta (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of IL-6 (pg/mL) During MMTT

Circulating levels of IL-6 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of IL-10 (pg/mL) During MMTT

Circulating levels of IL-10 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of IL-12 p40 (pg/mL) During MMTT

Circulating levels of IL-12 p40 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of IL-12 p70 (pg/mL) During MMTT

Circulating levels of IL-12 p70 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of IL-17 (pg/mL) During MMTT

Circulating levels of IL-17 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of Tumor Necrosis Factor (TNF)-Alpha (pg/mL) During MMTT

Circulating levels of tumor necrosis factor (TNF)-alpha (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedCirculating Levels of C Reactive Protein (CRP) (mg/L) During MMTT

Circulating levels of C reactive protein (CRP) (mg/L) at run in visit and end of treatment (day 28) performed during the MMTT

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedBody Fat Percentage

Body fat percentage measured by bioelectrical impedance scale

Time frame:
Run-in Visit (baseline), Days 1-28

Results for this outcome have not been posted.

Other pre-specifiedChange in the Percentage of Liver Fat Content

Change in the percentage of liver fat content assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedChange in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

The change in homeostatic model assessment for insulin resistance (HOMA-IR) at the end of treatment from the baseline

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedChange in Fasting Blood Glucose

The change in fasting blood glucose at the end of treatment from the baseline

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedChange in Serum Bile Acids

Change in serum bile acids at the end of treatment compared to the baseline

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedPhenotypic Taste Test

Phenotypic taste test (using commercially available test strips) at baseline

Time frame:
Run-in Visit (baseline)

Results for this outcome have not been posted.

Other pre-specifiedControl of Eating and Food Cravings

Control of eating and food craving assessed by the Control of Eating Questionnaire (CoEQ), which is a 21-item questionnaire designed to assess the intensity and type of food cravings and subjective sensations of appetite and mood according to an individual's experience over the last 7 days. Items on the CoEQ are assessed by 100-mm visual analogue scales (VAS). Subjects will mark their level with a vertical line on the horizontal line of the VAS scale. The numerical value will start at 1.0 cm and end 10.0 cm. Use a ruler to determine the numerical value (to the tenth decimal) associated with the line marked by subjects. Higher score indicates less control of eating and food cravings.

Time frame:
Screening, Days 1, 15, and 28

Results for this outcome have not been posted.

Other pre-specifiedChange in Indirect Calorimetry

Change in indirect calorimetry between Day 1 and Day 28

Time frame:
Day 1, Day 28

Results for this outcome have not been posted.

Other pre-specifiedArea Under the Curve (AUC) of Serum Level of Glucose (mg/dL) During MMTT

Changes in AUC of serum level of glucose (mg/dL) during MMTT between baseline and Day 28

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedArea Under the Curve (AUC) of Serum Level of Insulin (uIU/mL) During MMTT

Changes in AUC of serum level of insulin (uIU/mL) during MMTT between baseline and Day 28

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedArea Under the Curve (AUC) of Serum Level of C-peptide (ng/mL) During MMTT

Changes in AUC of serum levels of C-peptide (ng/mL) during MMTT between baseline and Day 28

Time frame:
Run-in Visit (baseline), Day 28

Results for this outcome have not been posted.

Other pre-specifiedChanges in Fecal Microbial Species and Their Relative Abundance

Changes in fecal microbial species and their relative abundance assessed by 16S rRNA gene sequencing

Time frame:
Day 1, Day 28

Results for this outcome have not been posted.

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARD-1010/12 (0%)0/12 (0%)6/12 (50%)
Most frequent other events
Most frequent other events
EventARD-101
Mild NauseaGastrointestinal disorders2/12
Mild EmesisGastrointestinal disorders1/12
Mild Common ColdInfections and infestations1/12
Mild HeadacheNervous system disorders1/12
Mild ConstipationGastrointestinal disorders1/12
Mild Heart BurnGastrointestinal disorders1/12
Mild HypoglycemiaEndocrine disorders1/12
Mild COVID-19Infections and infestations1/12
Mild DyspepsiaGastrointestinal disorders1/12

Baseline characteristics

Patients who completed treatment of ARD-101

Age, Continuous
Age, Continuous(years)ARD-101
Mean41 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)ARD-101
Female11
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARD-101
Hispanic or Latino5
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARD-101
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White9
More than one race0
Unknown or Not Reported1
Weight
Weight(Kilograms)ARD-101
Mean117.9 ± 21.8
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ARD-101
Mean42.7 ± 4.98
Height
Height(Centimeter)ARD-101
Mean165.6 ± 9.7
08

Study locations

1 site
  • Altman Clinical and Translational Research Institute, University of California, San Diego
    San Diego, California 92037, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Feb 2023, 11 months.

Results were first posted in Nov 2024, 1 year 9 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 31, 2022
StartActual
Mar 1, 2022
Primary completionActual
Feb 3, 2023
CompletionActual
Feb 3, 2023
Results first posted
Nov 14, 2024
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05215847
Lead sponsor
Aardvark Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Mar 1, 2022
Primary completion
Feb 3, 2023
Completion
Feb 3, 2023
Results posted
Nov 14, 2024
Last update
Feb 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denatonium acetate monohydrate

Start the discussion